Observational Study Evaluating Vericiguat Use and Safety in Korean Adults with Chronic Heart Failure and Reduced Ejection Fraction

What this Trial Is About

Researchers are observing people with chronic heart failure with reduced ejection fraction HFrEF, a condition where the heart pumps blood less effectively. This study focuses on patients in Korea who are prescribed vericiguat, a drug that increases the activity of an enzyme important for heart and blood circulation. The purpose is to collect real-world data on how vericiguat is used and its safety in regular medical practice. Participants receive vericiguat as prescribed by their doctors according to approved guidelines, without any intervention from the study team. Data collection includes medical records and routine practice visits. Participants are observed for up to 12 months or until death or withdrawal, whichever occurs first. The study tracks treatment patterns, including dose levels and duration of vericiguat use. During the study, researchers will monitor all adverse events, whether or not they are related to the drug. They will also collect information on serious heart-related outcomes such as death and hospital stays due to heart failure. The main outcome measures include the number of adverse events and cardiovascular events over the observation period. This approach helps understand vericiguats use and safety in everyday care over about one year.

An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting